Antibody-based detection of ERG rearrangement-positive prostate cancer.

摘要: TMPRSS2-ERG gene fusions occur in 50% of prostate cancers and result the overexpression a chimeric fusion transcript that encodes truncated ERG product. Previous attempts to detect products have been hindered by lack specific antibodies. Here, we characterize rabbit anti-ERG monoclonal antibody (clone EPR 3864; Epitomics, Burlingame, CA) using immunoblot analysis on cancer cell lines, synthetic constructs, chromatin immunoprecipitation, immunofluorescence. We correlated protein expression with presence rearrangements tissues combined immunohistochemistry (IHC) fluorescence situ hybridization (FISH) analysis. independently evaluated two patient cohorts observed confined cells high-grade prostatic intraepithelial neoplasia associated ERG-positive cancer, as well vessels lymphocytes (where has known biologic role). Image 131 cases demonstrated nearly 100% sensitivity for detecting rearrangement only 2 (1.5%) demonstrating strong without any fusion. The pathology evaluation 207 tumors had 95.7% 96.5% specificity determining cancer. In conclusion, this study qualifies demonstrates exquisite association between product expression. Given ease performing IHC versus FISH, may be useful molecularly subtyping based status suggests clinical utility needle biopsy evaluation.